Infectious Diseases Clinic, Mbarara University of Science and Technology, Mbarara, Uganda.
Int J Tuberc Lung Dis. 2012 Oct;16(10):1371-6. doi: 10.5588/ijtld.11.0589. Epub 2012 Aug 3.
We describe the presentation and outcome of care among patients with tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection from a prospective observational cohort in Uganda.
We analysed basic demographics, CD4+ counts, time of initiating antiretroviral therapy (ART), clinical and haematological parameters and outcome of care of 386 patients enrolled between February 2007 and March 2010.
At presentation, 56.7% of the patients were sputum-positive, 89.9% had new TB infection, 62.7% had wasting, 78.7% were anaemic, 72.1% had a CD4+ count of <200 cells/mm(3), 20.2% had pneumonia, 50.3% had oral thrush and 1.3% had Kaposi's sarcoma. Patients developing TB within 3 months of starting ART were less likely to have wasting, to be anaemic or to have a CD4+ count of <100 cells/mm(3). The cure, default and death rates were respectively 54.3%, 24% and 16%. At 8 months, 53 (13.7%) were confirmed dead, 119 (30.8%) were lost to follow-up, 28 (7.3%) were transferred out and 1 (0.3%) had treatment failure. Mortality and loss to follow-up were associated with failure to start ART and having a CD4+ count of <200 cells/mm(3).
In Uganda, TB-HIV patients present with severe immune suppression and are at increased risk of death and loss to follow-up, particularly those not on ART. There is need for early identification and improved follow-up of TB-HIV co-infected patients.
我们描述了在乌干达进行的一项前瞻性观察性队列研究中,结核分枝杆菌(TB)和人类免疫缺陷病毒(HIV)合并感染患者的就诊和治疗结局。
我们分析了 386 例患者的基本人口统计学数据、CD4+计数、开始抗逆转录病毒治疗(ART)的时间、临床和血液学参数以及治疗结局。
就诊时,56.7%的患者痰检阳性,89.9%的患者为新发结核病感染,62.7%的患者有消瘦,78.7%的患者贫血,72.1%的患者 CD4+计数<200 个细胞/mm³,20.2%的患者有肺炎,50.3%的患者有口腔鹅口疮,1.3%的患者有卡波西肉瘤。在开始 ART 后 3 个月内发生结核病的患者,消瘦、贫血或 CD4+计数<100 个细胞/mm³的可能性较低。治愈率、失访率和死亡率分别为 54.3%、24%和 16%。8 个月时,53 例(13.7%)被确认为死亡,119 例(30.8%)失访,28 例(7.3%)转院,1 例(0.3%)治疗失败。死亡率和失访率与未开始 ART 和 CD4+计数<200 个细胞/mm³有关。
在乌干达,TB-HIV 患者就诊时已处于严重免疫抑制状态,死亡和失访风险增加,尤其是未接受 ART 治疗的患者。需要早期识别和加强对 TB-HIV 合并感染患者的随访。